习勉 职务：
职称：副主任医师
专长：食管癌、肝癌等胸腹部肿瘤的放射治疗

主要简介 详细介绍 预约挂号

一、基本情况
专业特长：食管癌、肝癌等胸腹部肿瘤的放射治疗。
主要研究方向：1、食管癌的放化综合治疗；2、肝癌的精准放疗。
专家门诊时间：周三上午（越秀院区）、周一下午（黄埔院区）

二、学习及工作经历
1999.09-2004.06 郑州大学医学院临床医学系，本科
2004.09-2007.06 中山大学肿瘤防治中心肿瘤学，硕士
2010.09-2013.06 中山大学肿瘤防治中心肿瘤学，博士
2007.08-2010.12 中山大学肿瘤防治中心放疗科，住院医师
2010.12-2015.12 中山大学肿瘤防治中心放疗科，主治医师
2015.12-至今 中山大学肿瘤防治中心放疗科，副主任医师
2016-2017 美国M.D. Anderson肿瘤中心，访问****

三、学术团体任职
中国医药教育协会肿瘤放疗专委会常委；
广东省肝脏病学会综合治疗专委会常委；
广东省基层医药学会胸部肿瘤专业委员会常委；
广东省抗癌协会肝癌专业委员会青委会常委；
广东省抗癌协会食管癌专业委员会委员；
广东省医师协会胸外科分会食管癌专业组成员；
广东省医学会外科学会原发性肝癌学组成员；
广东省胸部肿瘤防治研究会靶向治疗专委会委员；
中国医师协会放疗专委会肝癌学组委员；
中国医师协会放疗专委会食管癌学组委员。

四、主持科研项目
1.国家自然科学基金青年项目：调强放射治疗诱导鼻咽癌放疗后第二恶性肿瘤发生的物理效应和调控研究。
2.广东省科技计划：不同放疗技术对鼻咽癌放疗后诱发恶性肿瘤的物理效应研究。
3.广东省食管癌研究所科技计划：局部晚期食管鳞癌多西他赛+顺铂诱导化疗联合同期放化疗的前瞻性随机对照Ⅱ期临床研究。
4.广东省食管癌研究所科技计划：应用PET-CT早期反应指导食管鳞癌根治性放化疗决策的随机对照Ⅱ期临床研究。
5.广东省自然科学基金：BATF转录调控IDO1信号通路诱导食管鳞癌放射抵抗的机制研究。
6.广州市科技计划：MTHFD1磷酸化调控食管鳞癌放射抵抗的机制研究。
7.中山大学肿瘤防治中心优秀青年人才计划 (2011-2015)。
8.中山大学肿瘤防治中心临床医学科学家培养计划 (2015-2019)。


一、基本情况
专业特长：食管癌、肝癌等胸腹部肿瘤的放射治疗。
主要研究方向：1、食管癌的放化综合治疗；2、肝癌的精准放疗。
专家门诊时间：周三上午（越秀院区）、周一下午（黄埔院区）

二、学习及工作经历
1999.09-2004.06 郑州大学医学院临床医学系，本科
2004.09-2007.06 中山大学肿瘤防治中心肿瘤学，硕士
2010.09-2013.06 中山大学肿瘤防治中心肿瘤学，博士
2007.08-2010.12 中山大学肿瘤防治中心放疗科，住院医师
2010.12-2015.12 中山大学肿瘤防治中心放疗科，主治医师
2015.12-至今 中山大学肿瘤防治中心放疗科，副主任医师
2016-2017 美国M.D. Anderson肿瘤中心，访问****

三、学术团体任职
中国医药教育协会肿瘤放疗专委会常委；
广东省肝脏病学会综合治疗专委会常委；
广东省基层医药学会胸部肿瘤专业委员会常委；
广东省抗癌协会肝癌专业委员会青委会常委；
广东省抗癌协会食管癌专业委员会委员；
广东省医师协会胸外科分会食管癌专业组成员；
广东省医学会外科学会原发性肝癌学组成员；
广东省胸部肿瘤防治研究会靶向治疗专委会委员；
中国医师协会放疗专委会肝癌学组委员；
中国医师协会放疗专委会食管癌学组委员。

四、主持科研项目
1.国家自然科学基金青年项目：调强放射治疗诱导鼻咽癌放疗后第二恶性肿瘤发生的物理效应和调控研究。
2.广东省科技计划：不同放疗技术对鼻咽癌放疗后诱发恶性肿瘤的物理效应研究。
3.广东省食管癌研究所科技计划：局部晚期食管鳞癌多西他赛+顺铂诱导化疗联合同期放化疗的前瞻性随机对照Ⅱ期临床研究。
4.广东省食管癌研究所科技计划：应用PET-CT早期反应指导食管鳞癌根治性放化疗决策的随机对照Ⅱ期临床研究。
5.广东省自然科学基金：BATF转录调控IDO1信号通路诱导食管鳞癌放射抵抗的机制研究。
6.广州市科技计划：MTHFD1磷酸化调控食管鳞癌放射抵抗的机制研究。
7.中山大学肿瘤防治中心优秀青年人才计划 (2011-2015)。
8.中山大学肿瘤防治中心临床医学科学家培养计划 (2015-2019)。

五、已发表论文（第一或通讯作者）
1.Zhou S, Yang H, Zhang J, Wang J, Liang Z, Liu S, Li Y, Pan Y, Zhao L, Xi M (corresponding author). Changes in indoleamine 2,3-dioxygenase 1 expression and CD8+ tumor-infiltrating lymphocytes after neoadjuvant chemoradiation therapy and prognostic significance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2020; 108(1):286-294.
2.Liu S, Wen J, Yang H, Li Q, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Zhao L, Liu H, Hu Y, Liu M, Fu J, Xi M (corresponding author). Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010. Eur J Cancer. 2020;138: 113-121.
3.Lan K, Zhu J, Zhang J, Zhou S, Yang Y, Feng Z, Zhang L, Wang S, Xi M (corresponding author). Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol. 2020; 149: 228-235.
4.Xu H, Lin M, Hu Y, Zhang L, Li Q, Zhu J, Wang S, Xi M (corresponding author). Lymphopenia during definitive chemoradiotherapy in esophageal squamous cell carcinoma: Association with dosimetric parameters and patient outcomes. Oncologist. 2021; in press.
5.Wu Y, Chen J, Zhao L, Li Q, Zhu J, Yang H, Guo S, Xi M (corresponding author). Prediction of pathologic response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma incorporating hematological biomarkers. Cancer Res Treat. 2021; in press.
6.Zhou S, Liu S, Lin C, Li Y, Ye L, Wu X, Jian Y, Dai Y, Ouyang Y, Zhao L, Liu M, Song L, Xi M (corresponding author). TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZ. Oncogene. 2020; 39(18): 3710-3725.
7.Fu Y, Xi M (co-first author), Pan Y, Chen J, Wang J, Liu S, Xu L, Zhou Z, Liu M, Chen M, Zhao L, Zhang Y. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: a retrospective cohort study. J Oncol. 2020; 2020: **.
8.Xi M, Yang Y, Zhang L, Yang H, Merrell KW, Hallemeier CL, Shen RK, Haddock MG, Hofstetter WL, Maru DM, Ho L, Wu CC, Liu M, Lin SH. Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer: the impact of histology on recurrence patterns and outcomes. Ann Surg. 2019; 269(4): 663-670.
9.Li Q, Zhou S, Liu S, Liu S, Yang H, Zhao L, Liu M, Hu Y, Xi M (corresponding author). Treatment-related lymphopenia predicts pathologic complete response and recurrence in esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2019; 26(9): 2882-2889.
10.Zhou S, Zhao L, Liang Z, Liu S, Li Y, Liu S, Yang H, Liu M, Xi M (corresponding author). Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression predicts poor pathologic response and recurrence in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. Cancers (Basel). 2019; 11(2). pii: E169.
11.Pan YX, Xi M (co-first author), Fu YZ, Hu DD, Wang JC, Liu SL, Chen JB, Xu L, Zhou ZG, Liu MZ, Chen MS, Zhao L, Zhang YJ. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: a retrospective propensity score matching study. Cancers (Basel). 2019; 11(8). pii: E1116.
12.Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence risk stratification after preoperative chemoradiation of esophageal adenocarcinoma. Ann Surg. 2018; 268(2): 289-295.
13.Shen L, Xi M (co-first author), Zhao L, Zhang X, Wang X, Huang Z, Chen Q, Zhang T, Shen J, Liu M, Huang J. Combination therapy after TACE for hepatocellular carcinoma with macroscopic vascular invasion: stereotactic body radiotherapy versus sorafenib. Cancers (Basel). 2018; 10(12). pii: E516.
14.Zhou S, Liu S, Zhang L, Guo S, Shen J, Li Q, Yang H, Feng Y, Liu M, Lin SH, Xi M (corresponding author). Recurrence risk based on pathologic stage after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma: implications for risk-based postoperative surveillance strategies. Ann Surg Oncol. 2018; 25(12): 3639-3646.
15.Zhou S, Zhang L, Luo L, Li Q, Shen J, Feng Z, Feng Y, Yang H, Liu MZ, Xi M (corresponding author). Failure pattern of elective nodal irradiation for esophageal squamous cell cancer treated with neoadjuvant chemoradiotherapy. Jpn J Clin Oncol. 2018; 48(9): 815-821.
16.Xi M, Liao Z, Deng W, Xu C, Komaki R, Blum M, Hofstetter WL, Ho L, Lin SH. A prognostic scoring model for the utility of induction chemotherapy prior to neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Oncol. 2017; 12(6): 1001-1010.
17.Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH. 18F-FDG PET response after induction chemotherapy can predict who will benefit from subsequent esophagectomy after chemoradiotherapy for esophageal adenocarcinoma. J Nucl Med. 2017; 58(11): 1756-1763.
18.Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity-modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis. Int J Radiat Oncol Biol Phys. 2017; 99(3): 667-676.
19.Xi M, Liao Z, Deng W, Komaki R, Ho L, Lin SH. Recursive partitioning analysis identifies pretreatment risk groups for the utility of induction chemotherapy prior to definitive chemoradiotherapy in esophageal cancer. Int J Radiat Oncol Biol Phys. 2017; 99(2): 407-416.
20.Xi M, Xu C, Liao Z, Hofstetter WL, Blum Murphy M, Maru DM, Bhutani MS, Lee JH, Weston B, Komaki R, Lin SH. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017; 124(2): 318-324.
21.Xi M, Zhang P, Zhang L, Yang YD, Liu SL, Li Y, Fu JH, Liu MZ. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. Jpn J Clin Oncol. 2017; 47 (8): 683-689.
22.Xi M, Lin SH. Recent advances in intensity modulated radiotherapy and proton therapy for esophageal cancer. Expert Rev Anticancer Ther. 2017; 17(7): 635-646.
23.Zhang P, Zhang L, Liu H, Zhao L, Li Y, Shen JX, Liu Q, Liu MZ, Xi M (corresponding author). Clinicopathologic characteristics and prognosis of tongue squamous cell carcinoma in patients with and without a history of radiation for nasopharyngeal carcinoma: a matched case-control study. Cancer Res Treat. 2017; 49(3): 695-705.
24.Zhang P, Zhao L, Zhu YJ, Qiu B, Guo SP, Li Y, Liu Q, Liu MZ, Xi M (corresponding author). Prognosis of fibrosarcoma in patients with and without a history of radiation for nasopharyngeal carcinoma. Ann Surg Oncol. 2017; 24(2): 434-440.
25.Xi M, Lin SH. Prognostic and predictive value of FDG-PET as an aid in oesophageal cancer management. EMJ Oncol. 2017; 5(1): 78-84.
26.Luo LL, Xi M (co-first author), Yang YD, Li QQ, Zhao L, Zhang P, Liu SL, Liu MZ. Comparative outcomes of induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone In esophageal squamous cell carcinoma. J Cancer. 2017; 8(17): 3441-3447.
27.Liu SL, Xi M (corresponding author), Yang H, Yang YD, Wu YJ, Zhao L, Zhang P, Luo LL, Liu MZ. Is there a correlation between clinical complete response and pathological complete response after neoadjuvant chemoradiotherapy for esophageal squamous cell cancer? Ann Surg Oncol. 2016; 23(1): 273-281.
28.习勉，梁健，孙文钊，邓小武，刘孟忠，张黎. 鼻咽癌调强放射治疗后放射诱发肿瘤发生风险的预测分析. 中国医学物理学杂志. 2016; 33(1): 6-9.
29.Liu SL, Yang H, Zhang P, Zhang L, Zhao L, Luo LL, Fu JH, Liu MZ, Xi M (corresponding author). Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: a matched case–control study. Radiother Oncol. 2015; 116(2): 262-268.
30.Zhang P, Xi M (co-first author), Zhao L, Qiu B, Liu H, Hu YH, Liu MZ. Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2015; 116(2): 257-261.
31.Zhang P, Xi M (co-first author), Zhao L, Li QQ, He LR, Liu SL, Shen JX, Liu MZ. Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastases alone. Radiat Oncol. 2014; 9(1): 256.
32.Zhang P, Xi M (co-first author), Li QQ, He LR, Liu SL, Zhao L, Shen JX, Liu MZ. The modified glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapy. J Cancer. 2014; 5(8): 689-695.
33.Zhang P, Xi M (co-first author), Zhao L, Shen JX, Li QQ, He LR, Liu SL, Liu MZ. Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma? PLoS One. 2014; 9(8): e105270.
34.Zhang P, Xi M (co-first author), Zhao L, Li QQ, He L, Liu S, Shen J, Liu MZ. Unilateral cervical nodal metastasis is an independent prognostic factor for esophageal squamous cell carcinoma undergoing chemoradiotherapy: A retrospective study. PLoS One. 2014; 9(6): e101332.
35.Xi M, Liu SL, Zhao L, Shen JX, Zhang L, Zhang P, Liu MZ. Prognostic factors and survival in patients with radiation-related second malignant neoplasms following radiotherapy for nasopharyngeal carcinoma. PLoS One. 2013; 8(12): e84586.
36.Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, Deng XW, Huang XY, Liu MZ. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One. 2013; 8(5): e63864.
37.Xi M, Zhang L, Li QQ, Zhao L, Zhang R, Liu MZ. Assessing the role of volumetric-modulated arc therapy in hepatocellular carcinoma. J Appl Clin Med Phys. 2013; 14(3): 4162.
38.Zhang L, Xi M (co-first author), Deng XW, Li QQ, Huang XY, Liu MZ. Four-dimensional CT-based evaluation of volumetric modulated arc therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Radiat Res. 2012; 53(5): 769-776.
39.Xi M, Zhang L, Liu MZ, Deng XW, Huang XY, Liu H. Dosimetric analysis of respiratory gated radiotherapy for hepatocellular carcinoma. Med Dosim. 2011; 36(2): 213-218.
40.Xi M, Liu MZ, Wang HX, Cai L, Zhang L, Xie CF, Li QQ. Radiation-induced sarcoma in patients with nasopharyngeal carcinoma: a single-institution study. Cancer. 2010; 116(23): 5479-5486.
41.Xi M, Liu MZ, Zhang L, Li QQ, Huang XY, Liu H, Hu YH. How many sets of 4DCT images are sufficient to determine internal target volume for liver radiotherapy? Radiother Oncol. 2009; 92(2): 255-259.
42.Xi M, Liu MZ, Deng XW, Zhang L, Huang XY, Liu H, Li QQ, Hu YH, Cai L, Cui NJ. Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT. Radiother Oncol. 2007; 84(3): 272-278.
43.习勉, 刘孟忠, 李巧巧, 等. 基于4DCT的腹部器官呼吸运动分析. 癌症. 2009; 28(9): 989-993.
44.习勉, 刘孟忠, 邓小武, 等. 基于四维CT原发性肝癌内靶体积的确定及剂量学研究. 中华放射肿瘤学杂志. 2009; 18(6): 435-439.
45.习勉, 刘孟忠, 邓小武, 等. 应用4D-CT技术确定肝癌内靶体积的研究. 癌症. 2007; 26(1): 1-8.


更新时间：2021年1月6日